Prostemics Co. Ltd (203690) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.036x

Based on the latest financial reports, Prostemics Co. Ltd (203690) has a cash flow conversion efficiency ratio of -0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-900.50 Million ≈ $-610.25K USD) by net assets (₩24.87 Billion ≈ $16.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Prostemics Co. Ltd (203690) total market value for the company's overall valuation and market capitalisation.

Prostemics Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Prostemics Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Prostemics Co. Ltd stock price for real-time trading data and today's change.

Prostemics Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Prostemics Co. Ltd ranked by their cash flow conversion efficiency. Review Prostemics Co. Ltd (203690) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
KINGS ENTERTAINMENT GROUP F:L12	N/A
GreenPower Motor Company Inc NASDAQ:GP	-0.021x
Prominence Energy Ltd AU:PRM	-0.075x
Cariboo Rose Resources Ltd V:CRB	0.014x
MW Trade S.A. WAR:MWT	-0.050x
Tijaria Polypipes Limited NSE:TIJARIA	-0.151x
RIVER TECH EO -005 F:9YQ	N/A
Kulthorn Kirby Public Company Limited BK:KKC	0.049x

Annual Cash Flow Conversion Efficiency for Prostemics Co. Ltd (2015–2025)

The table below shows the annual cash flow conversion efficiency of Prostemics Co. Ltd from 2015 to 2025. Also see 203690 asset base for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩25.96 Billion ≈ $17.59 Million	₩-10.11 Billion ≈ $-6.85 Million	-0.390x	-426.57%
2024-12-31	₩25.94 Billion ≈ $17.58 Million	₩-1.92 Billion ≈ $-1.30 Million	-0.074x	+67.06%
2023-12-31	₩30.43 Billion ≈ $20.62 Million	₩-6.84 Billion ≈ $-4.63 Million	-0.225x	+53.77%
2022-12-31	₩9.83 Billion ≈ $6.66 Million	₩-4.78 Billion ≈ $-3.24 Million	-0.486x	-325.35%
2021-12-31	₩13.93 Billion ≈ $9.44 Million	₩3.00 Billion ≈ $2.04 Million	0.216x	+199.11%
2020-12-31	₩21.47 Billion ≈ $14.55 Million	₩-4.67 Billion ≈ $-3.17 Million	-0.218x	-1349.04%
2019-12-31	₩28.35 Billion ≈ $19.21 Million	₩-425.74 Million ≈ $-288.52K	-0.015x	+79.48%
2018-12-31	₩31.89 Billion ≈ $21.61 Million	₩-2.33 Billion ≈ $-1.58 Million	-0.073x	+13.86%
2017-12-31	₩39.16 Billion ≈ $26.54 Million	₩-3.33 Billion ≈ $-2.25 Million	-0.085x	-164.99%
2016-12-31	₩44.86 Billion ≈ $30.40 Million	₩5.86 Billion ≈ $3.97 Million	0.131x	-17.60%
2015-12-31	₩39.38 Billion ≈ $26.69 Million	₩6.25 Billion ≈ $4.23 Million	0.159x	--

About Prostemics Co. Ltd

KQ:203690 Korea Biotechnology

Market Cap

$1.88 Million

₩2.78 Billion KRW

Market Cap Rank

#30197 Global

#2101 in Korea

Share Price

₩139.00

Change (1 day)

+0.00%

52-Week Range

₩139.00 - ₩139.00

All Time High

₩77250.00